...
首页> 外文期刊>Drug development and industrial pharmacy >In vitro/in vivo evaluation of felodipine micropowders prepared by the wet-milling process combined with different solidification methods
【24h】

In vitro/in vivo evaluation of felodipine micropowders prepared by the wet-milling process combined with different solidification methods

机译:湿磨法结合不同固化方法制备的非洛地平微粉的体外/体内评价

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In order to improve the in vitro dissolution rate and in vivo oral bioavailability of the poorly water soluble drug, felodipine (FELO), the wet-milling process was employed involving co-grinding with HPMC E5 and the in vitro release rate as investigated. After solidification by spray drying or freeze drying, the microsized powders were characterized in terms of their size, morphology, and in vitro dissolution rate. The oral bioavailability of this dry powder for suspension was evaluated in rats. After milling with 8% HPMC E5 and freeze drying, the powder mixture had an average particle size of 2.249 +/- 1.497 mm and displayed an excellent dissolution rate of up to 93.2% within 10 minutes. DSC and PXRD investigations confirmed the absence of any crystal transformation during the wet-milling process. Using two different solidification methods, powders were stable for 6 months with regard to their in vitro dissolution rate. Significantly improved bioavailability was obtained for the wet-milled suspension before solidification and freeze dried powders with 6.8-(p<0.001) and 3.6-fold (p<0.01) increases, respectively, compared with that of the un-milled FELO. Also, no marked difference (p>0.05) in bioavailability was seen for the spray dried powders. These effects suggest that the solidification method plays an important role in modifying the bioavailability of FELO after wet milling. Consequently, wet-milling is an effective technique to enhance the bioavailability of FELO and to maintain these benefits, freeze-drying is a feasible approach to solidifying the wet-milled suspension for industrial applications.
机译:为了提高水溶性较差的药物非洛地平(FELO)的体外溶出度和体内口服生物利用度,采用了湿磨工艺,其中包括与HPMC E5共研磨以及所研究的体外释放率。在通过喷雾干燥或冷冻干燥固化之后,根据其尺寸,形态和体外溶解速率对微粉进行表征。在大鼠中评估了该干粉悬浮液的口服生物利用度。用8%HPMC E5研磨并冷冻干燥后,该粉末混合物的平均粒径为2.249 +/- 1.497 mm,在10分钟内显示出高达93.2%的出色溶解率。 DSC和PXRD研究证实在湿磨过程中没有任何晶体转变。使用两种不同的固化方法,粉末的体外溶出速率稳定了6个月。与未碾磨的FELO相比,凝固前的湿磨悬浮液和冷冻干燥的粉末分别具有6.8-(p <0.001)和3.6倍(p <0.01)的增加,生物利用率得到了显着提高。同样,对于喷雾干燥的粉末,没有发现生物利用度的显着差异(p> 0.05)。这些效果表明,固化方法在改变湿磨后FELO的生物利用度方面起着重要作用。因此,湿磨是增强FELO的生物利用度并保持这些益处的有效技术,冷冻干燥是一种固化湿磨悬浮液以用于工业应用的可行方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号